Raltegravir in HIV-Exposed Neonates Raltegravir in HIV-Exposed Neonates
This study provides insight into the pharmacokinetics and safety of raltegravir in HIV-exposed neonates and discusses optimal dosing regimens.JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 23, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Neural Tube Defects After Raltegravir During Pregnancy Neural Tube Defects After Raltegravir During Pregnancy
Is there an association between raltegravir exposure during pregnancy and the development of neural tube defects?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 2, 2019 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Discontinuation of Dolutegravir, EVG/c and Raltegravir Discontinuation of Dolutegravir, EVG/c and Raltegravir
A new study examines the discontinuation rates among these integrase inhibitor regimens due to neuropsychiatric adverse events.HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2019 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Integrase Inhibitors Drop Virus Faster in Pregnant HIV Patients
(MedPage Today) -- Raltegravir, dolutegravir both appear safe and effective in late stage pregnancy (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 7, 2019 Category: Infectious Diseases Source Type: news

Medical News Today: What are integrase inhibitors for HIV?
Integrase inhibitors (INSTIs) are a class of HIV medication. They block an HIV enzyme, and this prevents the virus from multiplying in the blood. Some common brand names include Biktarvy, Tivicay, Vitekta, and Isentress. Here, learn about side effects and how these drugs work. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news

Dual Therapy With Raltegravir and a bPI in Pretreated HIV Dual Therapy With Raltegravir and a bPI in Pretreated HIV
Might treatment with raltegravir-containing combinations provide a feasible option for HIV patients who have failed previous therapies?HIV Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 19, 2018 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

HIV Drug Raltegravir Approved for Neonates HIV Drug Raltegravir Approved for Neonates
Raltegravir is the only integrase inhibitor approved in the US for treatment of HIV in newborns from birth to 4 weeks of age weighing at least 2 kg.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 12, 2017 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

Merck Receives FDA Approval for Isentress (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Newborns Weighing at Least 2 kg
KENILWORTH, N.J. November 29, 2017 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Isentress (raltegravir), the company’s integrase inhibitor,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 29, 2017 Category: Drugs & Pharmacology Source Type: news

Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Adverse Events of Raltegravir and Dolutegravir Adverse Events of Raltegravir and Dolutegravir
Do commonly reported toxic adverse events associated with these drugs factor into the decision to discontinue ART?AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 25, 2017 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Raltegravir Lowers HIV in Late Pregnancy (CME/CE)
(MedPage Today) -- Integrase inhibitor lowers viral load to undetectable levels (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - July 28, 2017 Category: Pediatrics Source Type: news

Dutrebis (Lamivudine and Raltegravir Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 3, 2017 Category: Drugs & Pharmacology Source Type: news

Isentress (Raltegravir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 12, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV
Isentress HD is given once daily in two 600-mg film-coated tablets in combination with other antiretroviral agents in appropriate patients with HIV-1 infection.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

FDA Clears Raltegravir (Isentress HD) for HIV
FDA Clears Once-Daily Raltegravir (Isentress HD) for HIV (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 31, 2017 Category: General Medicine Source Type: news